Loading
institutionsInstitution
Leipzig University Hospital / University Cancer Center Leipzig (UCCL)
Saxony's university hospital, whose cancer centre is led by gastro-oesophageal oncologist Florian Lordick and whose haematology department, under Uwe Platzbecker, leads European trials in myelodysplastic syndromes.
Also called: Universitätsklinikum LeipzigUCCLUniversitäres Krebszentrum Leipzig
Overview
Leipzig University Hospital houses the University Cancer Center Leipzig (UCCL), directed by Florian Lordick, a leader of European gastro-oesophageal cancer trials and guidelines. The Department of Hematology, Cellular Therapy and Hemostaseology, led by Uwe Platzbecker, coordinates the German MDS Study Group and led the COMMANDS and MEDALIST trials of luspatercept in anaemic myelodysplastic syndromes. The hospital is part of the Comprehensive Cancer Center Central Germany with Jena.
Location
Leipzig, DE
Type
hospital · Universität Leipzig
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#528 · 6 points (0 Newsweek + 0 NCI + 6 from 3 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-24.
Matched to University Hospital Leipzig, including child institutions. 381 works · 2,858 citations · 66% open access · 12% clinical trials · 1% reviews.
Oncology works per year
712022
842023
692024
842025
732026
Most works
- Vladan Vučinić57 works
- Uwe Platzbecker50 works
- Maximilian Merz42 works
- Anja Mehnert32 works
- Marco Herling28 works
- Klaus Hans Metzeler25 works
- Georg‐Nikolaus Franke24 works
- Madlen Jentzsch23 works
- Sigmar Stelzner22 works
- Ines Gockel22 works
Most cited
- Gastro-oesophageal cancer
- Myelodysplastic syndromes
- Cellular therapy
Florian Lordick
Director, University Cancer Center Leipzig; Professor of Oncology, University of Leipzig
Gastro-oesophageal cancerPerioperative therapyGuidelines
German GI oncologist who leads ESMO's gastric cancer guidelines and pivotal perioperative trials.
Uwe Platzbecker
Director, Department of Hematology, Cellular Therapy and Hemostaseology, University Hospital Leipzig
Myelodysplastic syndromesAnaemia therapeuticsAcute myeloid leukaemia
Led MEDALIST and COMMANDS, which made luspatercept a first-line treatment for anaemia in lower-risk MDS.
Similar pages
- TrialIMerge
Shares Uwe Platzbecker, Myelodysplastic syndromes / neoplasms (MDS).
- TrialCOMMANDS
Shares Uwe Platzbecker, Myelodysplastic syndromes / neoplasms (MDS).
- TrialMATTERHORN
Shares Florian Lordick, Gastric & gastro-oesophageal junction cancer.
- Key paperCOMMANDS: luspatercept versus epoetin alfa as first treatment for anaemia in lower-risk MDS needing transfusions
Shares Uwe Platzbecker, Myelodysplastic syndromes / neoplasms (MDS).
- TargetBCOR
Shares Myelodysplastic syndromes / neoplasms (MDS), Gastric & gastro-oesophageal junction cancer.
- TargetU2AF1
Shares Myelodysplastic syndromes / neoplasms (MDS), Gastric & gastro-oesophageal junction cancer.
- TermPlatinum drugs and PARP inhibitors: the newer leukaemia risk
Shares Myelodysplastic syndromes / neoplasms (MDS), Oesophageal cancer.